Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ImpACT-24A
Previous Study | Return to List | Next Study

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A) (ImpACT-24A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03767192
Recruitment Status : Terminated (Protocol Amendment)
First Posted : December 6, 2018
Last Update Posted : January 28, 2019
Sponsor:
Information provided by (Responsible Party):
BrainsGate

Brief Summary:
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Device: Active Stimulation Device: Sham Stimulation Not Applicable

Detailed Description:

This study was first registered as NCT00826059 on January 19, 2009 under the name ImpACT-24.

Background:

Recruitment to ImpACT-24 was halted, the protocol was amended and then the study was resumed. Later, it was decided to define the first part (before the halt) as a separate study - ImpACT-24A, and identify the continuation of the study as ImpACT-24B. ImpACT-24B continues to be registered as NCT00826059, and ImpACT-24A is registered in this new record.

Detailed Description:

A multi-center, multinational, randomized, double blind, sham control, adjunctive to Standard of Care, parallel arm study with ongoing DSMB review of accumulated safety data.

Screening:

Treatment should be initiated between 8 and 24 hours from stroke onset. All screened patients will be identified by patient number and will sign the informed consent prior to any study procedure initiation.

Period 1: Day 1-5

Day 1- Eligible subjects will be randomized in a 2:1 (ISS Stimulation: Sham Control) ratio:

Group 1: Implantation and ISS Stimulation during five consecutive days & Standard of Care Group 2: Implantation and Sham Stimulation during five consecutive days & Standard of Care The implantation will be performed by a trained physician. Stimulation/sham stimulation will be delivered Day 2-5 ISS / Sham Stimulation will be repeated during the following four consecutive days by trained personnel within 18-26 hours from preceding stimulation.

Day 5 / Day of Discharge. Following the last ISS /Sham Stimulation, explantation will be performed.

Subjects will continue with Standard of Care as needed and will be released from the hospital upon investigator's judgment.

Period 2: Day of Discharge - 90±7 days During this period both groups (ISS Stimulation and Sham Control) will be treated according to Standard of Care either at the hospital, rehabilitation center or at home.

Scheduled visits will be performed on day 30±7 and day 60 ±7, which will include safety and effectiveness assessments.

Final Visit Day 90±7 days: The final visit will be performed at the study site and will include safety and effectiveness evaluations.

Patients will be contacted by study personnel via telephone on Day 180±7 and on Day 360±7 in order to assess their quality of life status.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 327 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke
Actual Study Start Date : January 2009
Actual Primary Completion Date : January 2011
Actual Study Completion Date : March 2012

Arm Intervention/treatment
Experimental: Active Stimulation
Device: The Ischemic Stroke System SPG stimulation and standard of care
Device: Active Stimulation
SPG stimulation and standard of care

Sham Comparator: Sham Stimulation
Device: Sham control Sham stimulation and standard of care
Device: Sham Stimulation
Sham SPG stimulation and standard of care




Primary Outcome Measures :
  1. Sliding Dichotomy modified Rankin Scale (mRS) at 3 months [ Time Frame: 90 ±7 days ]

    Final global disability level on the modified Rankin scale (mRS) at 3 months better than expectation (sliding dichotomy analysis) ) assessed in the modified intention to treat (mITT) population defined as all randomized subjects receiving at least the minimal exposure of 1 treatment (ISS Stimulation or Sham Control) session out of the 5 planned sessions.

    mRS Scale:

    • 0 - No symptoms.
    • 1 - No significant disability. Able to carry out all usual activities, despite some symptoms.
    • 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
    • 3 - Moderate disability. Requires some help, but able to walk unassisted.
    • 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
    • 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
    • 6 - Dead.

  2. Number of participants with Serious Adverse Events [ Time Frame: 90 ±7 days ]
    Comparison between the active and sham stimulation groups of all serious adverse events (SAEs)

  3. Number of participants with neurological deterioration [ Time Frame: 10 days ]
    Comparison between the active and sham stimulation groups of the rate of neurological deterioration, defined as an increase of 4 or more points on the NIHSS related to any neurological event within the first 10 days after stroke onset

  4. Number of participants with implantation complications [ Time Frame: 90 ±7 days ]
    The rate of implantation complications as classified by the investigator

  5. Number of participants with stimulation-related adverse events [ Time Frame: 90 ±7 days ]
    Comparison between the active and sham stimulation groups of stimulation-related adverse events as classified by the investigator

  6. Mortality rate [ Time Frame: 90 ±7 days ]
    Comparison of mortality rates between the active and sham stimulation groups


Secondary Outcome Measures :
  1. Sliding Dichotomous 90-day mRS for patients with Aphasia at baseline [ Time Frame: 90 ±7 days ]

    Sliding Dichotomous 90-day mRS for patients with Aphasia at baseline

    mRS Scale:

    • 0 - No symptoms.
    • 1 - No significant disability. Able to carry out all usual activities, despite some symptoms.
    • 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
    • 3 - Moderate disability. Requires some help, but able to walk unassisted.
    • 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
    • 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
    • 6 - Dead.

  2. Binary NIHSS at Day 90 [ Time Frame: 90 ±7 days ]

    Binary NIHSS (success for score ≤1 or for ≥ 9-point improvement versus baseline)

    The NIHSS (National Institute of Health Stroke Score) is a 42-point scale that quantifies neurological deficits in 11 categories. Ratings for each item are scored with 3 to 5 grades, with 0 as normal.


  3. Stroke-related quality of life at 3 months: Stroke Impact Scale-16 [ Time Frame: 90 ±7 days ]

    Stroke-related quality of life at 3 months according to the Stroke Impact Scale-16 (SIS-16)

    The scale is based on a questionnaire with 16 items. Each answer ranges from 1 (poor) to 5 (good). A final single-item Recovery domain assesses the individual's perception of his/her recovery from stroke, where:

    0 = no recovery 100 = full recovery.

    Domain scores range from 0-100 and are calculated using the following equation:

    Domain score = [(Mean item score - 1) / (5-1) ] x 100




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: ≥ 18 years and ≤ 85 of both genders.
  2. Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories
  3. Baseline NIHSS ≥ 7 and ≤ 18
  4. Ability to initiate treatment within 8- 24 hours from stroke onset.

Exclusion Criteria:

  1. Intracranial hemorrhage or hemorrhagic transformation
  2. Massive stroke
  3. Acute ischemic stroke in the posterior circulation
  4. Minor stroke
  5. Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke
  6. Previous stroke in the last 6 months or pre-existing disability
  7. Patients with bleeding propensity or any condition in the oral cavity that prevents implantation
  8. Known cerebral arteriovenous malformation, cerebral aneurysm.
  9. Clinical suspicion of septic embolus.
  10. Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg)
  11. Serious systemic infection.
  12. Women known to be pregnant or having a positive or indeterminate pregnancy test.
  13. Patients with other implanted neural stimulator/ electronic devices (pacemakers).
  14. Life expectancy < 1 year from causes other than stroke.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03767192


Locations
Layout table for location information
United States, Tennessee
Erlanger Stroke Center
Chattanooga, Tennessee, United States, 37404
Germany
Erlangen University Clinic
Erlangen, Germany
Essen University Clinic
Essen, Germany
Heidelberg University Clinic
Heidelberg, Germany
Leipzig University Clinic
Leipzig, Germany
Munster University Clinic
Münster, Germany
Spain
Hospital Vall d'Hebron
Barcelona, Spain
Hospital Universitari de Girona
Girona, Spain
Sponsors and Collaborators
BrainsGate
Investigators
Layout table for investigator information
Study Director: Eyal Shay BrainsGate

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: BrainsGate
ClinicalTrials.gov Identifier: NCT03767192     History of Changes
Other Study ID Numbers: CLP1000500-24A
First Posted: December 6, 2018    Key Record Dates
Last Update Posted: January 28, 2019
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Keywords provided by BrainsGate:
acute ischemic stroke
randomized clinical trial
effectiveness
safety
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebral Infarction
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia